公开(公告)号：US12005116B2

公开(公告)日：2024-06-11

申请号：US18099044

申请日：2023-01-19

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04 ,  A61P31/14 ,  A61P37/04 ,  C12N15/861

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04 ,  A61P31/14 ,  A61P37/04 ,  C12N15/861 ,  A61K2039/55544 ,  C07K2319/00 ,  C12N2770/24234

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US11576967B2

公开(公告)日：2023-02-14

申请号：US17122578

申请日：2020-12-15

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04 ,  C12N15/861 ,  A61K39/00

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US10300131B2

公开(公告)日：2019-05-28

申请号：US15574427

申请日：2016-07-06

申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/00 ,  A61K39/21 ,  A61K39/295 ,  A61K48/00 ,  C12N15/86 ,  A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  C12N15/861

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.